Well done on picking up a few more Havenots. "As @NZ Trader says...

Well done on picking up a few more Havenots.

"As @NZ Trader says "PAA is a Take Over Target as it stands , 100%"

This is the great unknown at the moment and I wish I had more insight into how BP thinks. But in my amateur way I look at it in the following way. If BP want to tackle ALS, AD, PD and a few more with a potential income in excess of 6 Billion a year they need to.

1. Have a drug in the first place, that can cross the brain/blood barrier.
2. Spend a minimum of 5 years [Probably more] taking it from pre clinical through to registration.
3. Spend a minimal of 1 billion dollars, while knowing there is a very likely chance it will fail.

Or they can snatch up a drug.

1. showing great potential, that Berry Consultants chose to showcase at a recent conference in Stockholm.
2. Is possibly 12 months away from approval.
3. That has the tablet manufacturing well advanced.
4. That has ODD attached for ALS.
5. That they would only have to spend an additional 20-30 million [AUD] on. Plus marketing etc.

And if that does not happen PAA can continue taking it forward while adding more value.

In the 5 years it would take them to get something up [or fail] how much revenue could something like Monepantel make them ? I suggest a minimal of 30 Billion gross turnover.

Time will tell.